# The Progeria Research Foundation 10th International Scientific Workshop, "Researching Possibilities, ExTENding Lives"

> **NIH NIH R13** · PROGERIA RESEARCH FOUNDATION, INC. · 2021 · $50,000

## Abstract

Overview: Hutchinson-Gilford progeria syndrome (HGPS or Progeria) is a rare, fatal segmental premature aging
disease caused by a splice site mutation in the LMNA gene. Children with Progeria die from heart attacks or
strokes at an average age of 14.6 years following premature, progressive atherosclerosis. The mission of The
Progeria Research Foundation (PRF) is to find treatments and the cure for Progeria and its aging-related
disorders, including cardiovascular disease (CVD). The upcoming PRF 10th International Scientific Workshop
on Progeria will be held in Cambridge, MA on November 2-4, 2020. All prior PRF workshops were co-funded by
the National Institutes of Health. With record-high numbers of both peer-reviewed publications on Progeria and
requests for cell lines from the PRF Cell and Tissue Bank for preclinical explorations, as well as first-ever
submissions to the FDA for both drug approval and a disease biomarker, this field of study is on the verge of
major advancements. Objectives: to create an ideal environment for collaborative discussion between basic
and clinical scientists about how their collective experience with Progeria can accelerate scientific progress for
Progeria, CVD and aging; to coordinate research activities; and to develop future activities in these fields towards
better health for those with Progeria and for the general aging population. Program: The meeting starts with an
inspiring evening session. Progeria clinical trial patients, along with their parents, will share their experiences,
feelings, and extraordinary personalities with the scientific audience. This is followed by a plenary presentation
by pioneer David Liu, PhD (Broad Inst.), who will usher the attendees into the world of genetic editing and its
endless possibilities for application to Progeria, CVD and aging. Day 2 will start with critical emerging Progeria
model systems and disease biomarkers, followed by an integrated basic and clinical cardio/neurovascular panel
session. Peppered throughout the program are seasoned HGPS, CVD and aging experts, mixed with junior
investigators who will undoubtedly lead this field over the coming decade. On day 3, an early morning “coffee
talk” session will see junior investigators and students receiving mentorship from world experts. Next, data on
the only active Progeria clinical trials worldwide will be presented. Future interventions then take the stage, with
new data from prestigious investigators such as NIH Director Francis S. Collins, MD, PhD and NCI Distinguished
Investigator Tom Misteli, PhD on RNA and DNA therapeutics, and 3 talks on post-translational pathway-based
intervention, including drug repurposing. A poignant all-hands discussion on the effects of COVID-19 on our
research community and summation and key findings sessions, moderated by world-renowned aging
investigator Judith Campisi, PhD, will galvanize the group with one common goal: to bring hope to those with
Progeria for a long and healthy futu...

## Key facts

- **NIH application ID:** 10145384
- **Project number:** 1R13AG071212-01
- **Recipient organization:** PROGERIA RESEARCH FOUNDATION, INC.
- **Principal Investigator:** LESLIE B GORDON
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $50,000
- **Award type:** 1
- **Project period:** 2021-01-15 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10145384

## Citation

> US National Institutes of Health, RePORTER application 10145384, The Progeria Research Foundation 10th International Scientific Workshop, "Researching Possibilities, ExTENding Lives" (1R13AG071212-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10145384. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*